These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 34029540)

  • 41. Knockdown of Enhancer of Zeste Homolog 2 Affects mRNA Expression of Genes Involved in the Induction of Resistance to Apoptosis in MOLT-4 Cells.
    Naimi A; Safaei S; Entezari A; Solali S; Hassanzadeh A
    Anticancer Agents Med Chem; 2020; 20(5):571-579. PubMed ID: 32000648
    [TBL] [Abstract][Full Text] [Related]  

  • 42. 2,2- dimethylbenzopyran derivatives containing pyridone structural fragments as selective dual-targeting inhibitors of HIF-1α and EZH2 for the treatment of lung cancer.
    Xu H; Zhang J; Zhuang J; Chen Y; Chen L; Wang J; Cao R; Liu F; Wang K; Zhang X; Wang L; Chen G
    Bioorg Chem; 2024 Jun; 147():107419. PubMed ID: 38703440
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dual inhibition of enhancer of zeste homolog 1/2 overactivates WNT signaling to deplete cancer stem cells in multiple myeloma.
    Nakagawa M; Fujita S; Katsumoto T; Yamagata K; Ogawara Y; Hattori A; Kagiyama Y; Honma D; Araki K; Inoue T; Kato A; Inaki K; Wada C; Ono Y; Yamamoto M; Miura O; Nakashima Y; Kitabayashi I
    Cancer Sci; 2019 Jan; 110(1):194-208. PubMed ID: 30343511
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Enhanced cancer therapy with pH-dependent and aptamer functionalized doxorubicin loaded polymeric (poly D, L-lactic-co-glycolic acid) nanoparticles.
    Saravanakumar K; Hu X; Shanmugam S; Chelliah R; Sekar P; Oh DH; Vijayakumar S; Kathiresan K; Wang MH
    Arch Biochem Biophys; 2019 Aug; 671():143-151. PubMed ID: 31283911
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sclareol-loaded hyaluronan-coated PLGA nanoparticles: Physico-chemical properties and in vitro anticancer features.
    Cosco D; Mare R; Paolino D; Salvatici MC; Cilurzo F; Fresta M
    Int J Biol Macromol; 2019 Jul; 132():550-557. PubMed ID: 30946903
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Encapsulation of 4-oxo-
    Mrunalini B; Dev A; Kushwaha AC; Sardoiwala MN; Karmakar S
    Nanoscale; 2024 Aug; 16(34):16075-16088. PubMed ID: 39087878
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Selective inhibition of EZH2 by ZLD1039 blocks H3K27 methylation and leads to potent anti-tumor activity in breast cancer.
    Song X; Gao T; Wang N; Feng Q; You X; Ye T; Lei Q; Zhu Y; Xiong M; Xia Y; Yang F; Shi Y; Wei Y; Zhang L; Yu L
    Sci Rep; 2016 Feb; 6():20864. PubMed ID: 26868841
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
    Rizq O; Mimura N; Oshima M; Saraya A; Koide S; Kato Y; Aoyama K; Nakajima-Takagi Y; Wang C; Chiba T; Ma A; Jin J; Iseki T; Nakaseko C; Iwama A
    Clin Cancer Res; 2017 Aug; 23(16):4817-4830. PubMed ID: 28490465
    [No Abstract]   [Full Text] [Related]  

  • 49. Pharmacokinetic Consequences of PLGA Nanoparticles in Docetaxel Drug Delivery.
    Rafiei P; Haddadi A
    Pharm Nanotechnol; 2017; 5(1):3-23. PubMed ID: 28948907
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Polycomb group proteins EZH2 and EED directly regulate androgen receptor in advanced prostate cancer.
    Liu Q; Wang G; Li Q; Jiang W; Kim JS; Wang R; Zhu S; Wang X; Yan L; Yi Y; Zhang L; Meng Q; Li C; Zhao D; Qiao Y; Li Y; Gursel DB; Chinnaiyan AM; Chen K; Cao Q
    Int J Cancer; 2019 Jul; 145(2):415-426. PubMed ID: 30628724
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Design, Synthesis, and Biological Evaluation of Potent EZH2/LSD1 Dual Inhibitors for Prostate Cancer.
    Le M; Lu W; Tan X; Luo B; Yu T; Sun Y; Guo Z; Huang P; Zhu D; Wu Q; Ganesan A; Wen S
    J Med Chem; 2024 Sep; 67(17):15586-15605. PubMed ID: 39196854
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Enhancer of zeste 2 polycomb repressive complex 2 subunit promotes sorafenib resistance of hepatocellular carcinoma though insulin-like growth factor 1 receptor.
    Hu J; Zhang J; Sun F; Qi M; Su P; Liu H; Gao L; Jiao M; Wu Z; Xiang L; Han B
    Anticancer Drugs; 2019 Aug; 30(7):e0746. PubMed ID: 31305292
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibition of melanoma metastasis by dual-peptide PLGA NPS.
    Arruda DC; de Oliveira TD; Cursino PHF; Maia VSC; Berzaghi R; Travassos LR; Tada DB
    Biopolymers; 2017 Sep; 108(5):. PubMed ID: 28547860
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Biomimetic nanoparticle loading obatoclax mesylate for the treatment of non-small-cell lung cancer (NSCLC) through suppressing Bcl-2 signaling.
    Chen S; Ren Y; Duan P
    Biomed Pharmacother; 2020 Sep; 129():110371. PubMed ID: 32563984
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Identification of a chemical modulator of EZH2-mediated silencing by cell-based high-throughput screening assay.
    Murashima A; Shinjo K; Katsushima K; Onuki T; Kondoh Y; Osada H; Kagaya N; Shin-Ya K; Kimura H; Yoshida M; Murakami S; Kondo Y
    J Biochem; 2019 Jul; 166(1):41-50. PubMed ID: 30690451
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Molecular docking simulation, synthesis and 3D pharmacophore studies of novel 2-substituted-5-nitro-benzimidazole derivatives as anticancer agents targeting VEGFR-2 and c-Met.
    Ibrahim HA; Awadallah FM; Refaat HM; Amin KM
    Bioorg Chem; 2018 Apr; 77():457-470. PubMed ID: 29453077
    [No Abstract]   [Full Text] [Related]  

  • 57. Synthesis and evaluation of novel benzimidazole derivatives as sirtuin inhibitors with antitumor activities.
    Yoon YK; Ali MA; Wei AC; Choon TS; Osman H; Parang K; Shirazi AN
    Bioorg Med Chem; 2014 Jan; 22(2):703-10. PubMed ID: 24387981
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Synthesis and biological evaluation of a new series of benzimidazole derivatives as antimicrobial, antiquorum-sensing and antitumor agents.
    El-Gohary NS; Shaaban MI
    Eur J Med Chem; 2017 May; 131():255-262. PubMed ID: 28334654
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of different molecular weight PLGA on flurbiprofen nanoparticles: formulation, characterization, cytotoxicity, and
    Öztürk AA; Yenilmez E; Şenel B; Kıyan HT; Güven UM
    Drug Dev Ind Pharm; 2020 Apr; 46(4):682-695. PubMed ID: 32281428
    [No Abstract]   [Full Text] [Related]  

  • 60. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
    Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI
    Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.